Recombinant Papio anubis Histone-lysine N-methyltransferase setd3 (SETD3), partial

What is SETD3 and what is its primary function?

SETD3 is a protein that functions as an actin-specific histidine N-methyltransferase, catalyzing the methylation of histidine 73 (H73) in β-actin. While initially reported as a histone methyltransferase that methylates histone H3, recent research has conclusively demonstrated that its primary physiological role is to methylate actin . This modification is highly conserved across eukaryotes, with actin from wildtype cells being >90% methylated at H73, suggesting significant functional importance .

The methylation of actin H73 has been shown to stabilize actin filaments, as evidenced by increased depolymerization rates in non-methylated actin . When SETD3 is knocked out in cells, there is a complete absence of methylation at β-actin H73, resulting in decreased F-actin content, loss of cytoskeleton integrity, and an increased glycolytic phenotype .

How is SETD3 structurally organized?

SETD3 contains two distinct domains that contribute to its function:

• SET domain: Responsible for the methyltransferase activity. This domain contains the active site with key residues like Asn255 that form critical hydrogen bonds with the target histidine residue .

• Rubisco LSMT substrate-binding domain: Thought to contribute to substrate recognition and specificity .

This dual-domain structure is believed to be the structural basis for SETD3's potential dual substrate specificity . Crystal structures have shown that the catalytic mechanism involves positioning the N3 atom of histidine or the ε-amino nitrogen of lysine in the same position relative to the incoming methyl group of SAM .

How conserved is SETD3 across species?

SETD3 demonstrates remarkable evolutionary conservation:

• Vertebrates show 75-98% sequence identity with rat SETD3

• Insects exhibit 35-40% identity

• Plants and fungi maintain approximately 30% identity

Notably, SETD3 orthologues are absent in certain organisms like Saccharomyces cerevisiae and Naegleria gruberi, which correspondingly lack actin H73 methylation . This co-evolutionary relationship between SETD3 and actin methylation across species strongly supports the identification of SETD3 as the actin-specific histidine N-methyltransferase .

How can SETD3 methyltransferase activity be accurately measured?

Several complementary approaches can be used to measure SETD3 methyltransferase activity:

• Radiometric assay: This method measures the incorporation of [³H]methyl groups from [³H]SAM into recombinant β-actin or synthetic peptides. As described in the literature, this approach can be used to track enzyme purification and kinetic analysis . Using recombinant human β-actin and H73A β-actin mutant as a negative control ensures specificity for H73 methylation .

• Mass spectrometry: For protein substrates, digestion followed by LC-MS/MS can identify methylated peptides. For synthetic peptides, direct MALDI-TOF or ESI-MS analysis can be employed .

• Western blotting with methylation-specific antibodies: This provides a more accessible approach but depends on antibody specificity and is semi-quantitative.

When measuring SETD3 activity, it's crucial to include appropriate controls such as the H73A β-actin mutant to ensure specificity of the methyltransferase activity being measured .

What expression systems and purification methods yield optimal SETD3 activity?

The purification of actin-specific histidine N-methyltransferase from rat leg muscle provides insights into effective purification strategies:

• Sequential chromatography steps including:

  • Myofibrillar extraction

  • DEAE-Sepharose chromatography

  • Q-Sepharose chromatography

  • Reactive Red 120-agarose chromatography

  • Superdex 200 size exclusion chromatography

For recombinant SETD3 expression, both bacterial and eukaryotic expression systems can be employed, with careful attention to maintaining protein stability and enzymatic activity through appropriate buffer conditions.

How does substrate conformation affect SETD3 activity?

Substrate conformation significantly influences SETD3 activity. Research has shown that:

• Denatured or quasi-native actin serves as a good substrate for SETD3, whereas native actin containing ATP or ADP is poorly methylated .

• The presence of nucleotides may create structural hindrance preventing SETD3 from accessing the H73 residue, particularly if SETD3 interacts with actin through the nucleotide-binding cleft .

This has led to the hypothesis that nucleotide-free actin monomers in complex with specific actin-binding proteins may be the physiological substrate for SETD3 . This resembles the activity of other known protein histidine N-methyltransferases, such as the yeast Yil110w protein, which methylates the ribosomal Rpl3 protein only when it's associated with the ribosome .

How can SETD3 be engineered to alter its substrate specificity?

Engineering SETD3 to modify substrate specificity involves targeted mutations in the active site. Key strategies include:

• Conversion from histidine to lysine specificity:

  • The N255F substitution replaces the asparagine that hydrogen bonds with histidine

  • The W273A substitution creates an active site environment more favorable for lysine

  • The double mutant (N255F/W273A) shows a 13-fold preference for lysine over histidine

• Structural basis for specificity switching:

  • X-ray crystallography has shown that the N3 atom of histidine and the ε-amino nitrogen of lysine occupy the same position relative to the incoming methyl group of SAM

  • This spatial arrangement is critical for direct methyl transfer during catalysis

The ability to switch SETD3's specificity from histidine to lysine through these mutations demonstrates the plasticity of the active site and provides valuable tools for studying methyltransferase mechanisms .

How do the kinetic properties of wild-type SETD3 compare to engineered variants?

Wild-type SETD3 demonstrates a strong preference for histidine methylation over lysine methylation. The enzyme shows >1300-fold greater catalytic efficiency (kcat/Km) for histidine than for lysine . This preference is likely due to the unique hydrogen-bonding interaction between Asn255 in SETD3 and the target histidine residue .

When comparing activity on synthetic peptides:

• SETD3 methylates actin peptide H at least 10-fold more efficiently than histone peptide H3N4

• Activity with histone peptide is at least 4000-fold lower than with recombinant β-actin

The engineered N255F/W273A double mutant reverses this preference, exhibiting a 13-fold preference for lysine over histidine . This shift in substrate specificity demonstrates how targeted mutations can fundamentally alter the catalytic properties of methyltransferases.

What are the consequences of SETD3 deficiency on cytoskeletal organization?

SETD3 deficiency has significant effects on cytoskeletal organization, primarily through its impact on actin methylation:

• Decreased F-actin content: Confocal microscopy with TRITC-phalloidin staining reveals a clear decrease in F-actin in SETD3-knockout cells, where actin is largely non-methylated at H73 .

• Loss of cytoskeletal integrity: This effect becomes more pronounced with longer culture times (48 hours versus 24 hours), suggesting progressive deterioration of the cytoskeleton .

• Increased actin depolymerization: Non-methylated actin filaments show an accelerated rate of depolymerization, resulting in faster conversion of more stable ATP-F-actin to less stable ADP-F-actin .

• Reduced thermal stability: Thermal stability assays show that methylated actin from wildtype cells is more thermostable than non-methylated actin from SETD3-knockout cells .

These phenotypic changes resemble those present in cancer cells, suggesting that hypomethylation of actin might be involved in tumorigenesis .

How does SETD3 contribute to cellular metabolism?

SETD3 deficiency results in an increased glycolytic phenotype in cells . This metabolic shift may be linked to the cytoskeletal changes caused by the absence of actin H73 methylation, as the cytoskeleton is known to influence cellular metabolism through various mechanisms.

The connection between SETD3, actin methylation, and cellular metabolism represents an important area for future research, potentially linking cytoskeletal dynamics to metabolic regulation in both normal physiology and disease states.

What experimental approaches can be used to investigate SETD3 function in complex cellular contexts?

Multiple complementary approaches can be employed to investigate SETD3 function:

• Genetic manipulation:

  • CRISPR/Cas9-mediated knockout in cell lines (e.g., HAP1) or model organisms

  • RNAi-mediated knockdown for partial depletion

  • Comparison of multiple knockout clones to exclude artifacts associated with clonal populations

• Imaging techniques:

  • 3D confocal microscopy with F-actin staining using TRITC-phalloidin to visualize cytoskeletal organization

  • Live-cell imaging to capture dynamic changes in actin filaments

• Biochemical assays:

  • Thermal stability assays to compare stability of methylated versus non-methylated actin

  • Actin polymerization/depolymerization kinetics

  • Interaction studies with actin-binding proteins

• Proteomic analyses:

  • Mass spectrometry to quantify actin methylation levels

  • Identification of potential SETD3-interacting proteins and complexes

Integration of these approaches provides a comprehensive understanding of SETD3's roles in cellular physiology and cytoskeletal dynamics.

What are the implications of SETD3's dual methyltransferase activity?

SETD3's potential dual methyltransferase activity toward both histidine and lysine residues represents a significant finding in the field of protein methylation:

• Evolutionary perspective: SETD3 is the first identified SET-domain-containing enzyme displaying dual methyltransferase specificity toward both lysine and histidine residues in proteins .

• Substrate promiscuity: While SETD3 shows a strong preference for histidine methylation (particularly actin H73), it can also methylate lysine residues with much lower efficiency . This substrate promiscuity can be enhanced or reversed through targeted mutations .

• Implications for other methyltransferases: The dual specificity of SETD3 raises questions about the substrate specificity of other SET-domain-containing enzymes, suggesting they might have broader substrate ranges than previously recognized .

• Potential for discovering new methylation targets: The dual specificity of SETD3 opens the possibility that it may methylate both histidine and lysine residues in various proteins under different cellular conditions or in specific contexts.

What are the most promising directions for future SETD3 research?

Several promising directions for future SETD3 research include:

• Identification of additional substrates:

  • Proteome-wide analyses to identify other histidine-methylated proteins

  • Investigation of potential physiological lysine methylation substrates

  • Exploration of substrate recognition determinants

• Structural biology:

  • Obtaining structures of SETD3 bound to actin

  • Understanding the structural basis for substrate specificity

  • Investigating conformational changes during catalysis

• Physiological and pathological roles:

  • Detailed characterization of SETD3 knockout animal models

  • Investigation of SETD3 in disease contexts, particularly cancer

  • Exploration of tissue-specific functions

• Regulatory mechanisms:

  • Understanding how SETD3 interacts with potential protein complexes, similar to how other SET-domain-containing methyltransferases function in complexes like COMPASS

  • Investigating post-translational modifications that might regulate SETD3 activity

These research directions will expand our understanding of SETD3 biology and potentially reveal new therapeutic targets.

What remains unknown about SETD3 in primate models including Papio anubis?

Despite significant advances in understanding SETD3 function, several aspects remain unexplored in primate models including Papio anubis:

• Species-specific regulation:

  • Transcriptional and post-transcriptional regulation of SETD3 in different primate tissues

  • Potential primate-specific protein interactions

  • Comparative analysis of SETD3 expression patterns across primate lineages

• Physiological relevance:

  • Tissue-specific functions in primate physiology

  • Potential roles in primate-specific developmental processes

  • Comparative analysis of phenotypes resulting from SETD3 deficiency across primate models

• Evolutionary adaptations:

  • Analysis of selective pressures on SETD3 in the primate lineage

  • Identification of primate-specific sequence variations that might affect function

  • Comparative studies of substrate specificity across primate species

• Pathological implications:

  • Roles in primate-specific disease models

  • Potential involvement in neurodegenerative disorders that disproportionately affect primates

  • Therapeutic targeting strategies specific to primate SETD3

Addressing these knowledge gaps would provide valuable insights into the function and importance of SETD3 in primate biology and potentially reveal novel therapeutic targets for human diseases.